Thursday, May 8, 2025
  • Login
No Result
View All Result
ForexTV
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
No Result
View All Result
ForexTV
No Result
View All Result
ADVERTISEMENTS
club Felene

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

by GlobeNewswire
March 26, 2025
in Top News
Reading Time: 7 mins read

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab), a biologic indicated for treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps. Global sales of Xolair in 2024 were about USD $4.4 billion [1]. 

“This represents an important step in the development of our proposed biosimilar to Xolair, with the key goal to increase patient access to an important biologic,” said Joseph McClellan, Chief Scientific Officer of Alvotech.

“At Kashiv, we are committed to developing high-quality, cost-effective therapies. The successful acceptance by MHRA of the marketing authorization for AVT23 reflects our dedication to innovation and improving access to vital biosimilars on a global scale,” said Chirag and Chintu Patel, Executive Chairman and Co-Founders of Kashiv Biosciences.

Dr Nick Warwick, Chief Medical Officer of Advanz Pharma, stated, “This achievement marks a significant step in expanding treatment options for patients and reinforces Advanz Pharma’s dedication to enhancing access to specialty, hospital, and rare disease medications.”

Alvotech and Advanz Pharma announced in February 2023 that the companies had entered into a commercialization agreement for AVT23. In May 2023, the partners announced an expansion of the strategic partnership, to include five additional biosimilar candidates under development by Alvotech. Alvotech and Kashiv announced in October 2023 that the companies had entered into a licensing agreement for AVT23.

About AVT23
AVT23 is a proposed biosimilar to Xolair® (omalizumab). Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E (IgE). Xolair, which contains omalizumab, is indicated for severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) [2]. AVT23 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.

Sources
[1] Financial Reports from Roche Group and Novartis
[2] MHRA Product Information for Xolair®

Use of trademarks
Xolair is a registered trademark of Novartis AG.

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “aim” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability get marketing approval for AVT23 in the UK and other jurisdictions; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech’s estimates of expenses and profitability; (6) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company’s business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.

ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com

  • Author
  • Recent Posts
GlobeNewswire
GlobeNewswire
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
GlobeNewswire
Latest posts by GlobeNewswire (see all)
  • FG Communities Completes Manufactured Housing Acquisition in Morganton, North Carolina - May 8, 2025
  • AGCO issues penalties of $151,000 against Great Canadian Entertainment for alleged age verification failures - May 8, 2025
  • CarMax Returns as Front-of-Jersey Sponsor for Richmond Ivy Soccer Club - May 8, 2025
ADVERTISEMENTS
ForexTV Digital Marketing

Related Posts

FG Communities Completes Manufactured Housing Acquisition in Morganton, North Carolina

by GlobeNewswire
May 8, 2025
0

Acquisition grows presence in Western North CarolinaMOORESVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- FG Communities, whose mission is to...

AGCO issues penalties of $151,000 against Great Canadian Entertainment for alleged age verification failures

by GlobeNewswire
May 8, 2025
0

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- The Alcohol and Gaming Commission of Ontario (AGCO) has issued $151,000 in penalties...

CarMax Returns as Front-of-Jersey Sponsor for Richmond Ivy Soccer Club

by GlobeNewswire
May 8, 2025
0

CarMax Returns as Front-of-Jersey Sponsor for Richmond Ivy Soccer Club CarMax Returns as Front-of-Jersey Sponsor for Richmond Ivy Soccer Club...

Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight

by GlobeNewswire
May 8, 2025
0

The growing prevalence of chronic and infectious diseases is a major driver behind the rising demand for immunodiagnostics. Moreover, the...

High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight

by GlobeNewswire
May 8, 2025
0

As per DelveInsight’s estimates, among the 7MM, the US captured the highest market of high- and low-grade serous ovarian cancer...

McEwen Mining: Q1 2025 Results

by GlobeNewswire
May 8, 2025
0

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) today reported its first quarter results...

Next Post

Hairy Houdini LLC Expands Pet Waste Removal Services to Additional Locations

Please login to join discussion
ADVERTISEMENTS

Latest Posts

  • FG Communities Completes Manufactured Housing Acquisition in Morganton, North Carolina May 8, 2025
  • AGCO issues penalties of $151,000 against Great Canadian Entertainment for alleged age verification failures May 8, 2025
  • CarMax Returns as Front-of-Jersey Sponsor for Richmond Ivy Soccer Club May 8, 2025
  • Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight May 8, 2025
  • High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight May 8, 2025
  • About Us
  • Advertise
  • Careers
  • Contact
Privacy Policy / Terms and Conditions

© 2024 ForexTV.com

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Cookie Policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
No Result
View All Result
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates

© 2024 ForexTV.com